After more than 25 years of commercial use with almost 20 parenteral drug products, lipid nanoparticles (LNPs) are having a breakout moment due to their use with a range of COVID-19 vaccines in clinical development. Beyond pandemics, LNPs are now considered a gold standard drug delivery technology for gene and cell-based therapies as well as other nanomedicines. They are also being increasingly considered across application areas including anti-cancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand-targeted formulations and imaging contrast agents.
In this webinar, Evonik will review key delivery requirements and best-practices for the formulation development and manufacturing of LNP-based drug products. In particular, our expert speakers will discuss the delivery of small molecule drugs and of nucleic acid (NA)-based therapeutics.